In the EU, GOHIBIC (vilobelimab) has been granted marketing authorization under exceptional circumstances for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress ...

“Our preclinical studies with our new orally administered, small molecule C5aR inhibitor INF904 have shown potential for INF904 to inhibit C5a-induced signaling through its receptor C5a ...

InflaRx continues its mission as a pioneering anti-inflammatory therapeutics company targeting the complement system, namely by developing inhibitors of key immune regulators C5a and its receptor C5aR ...

Compared with individuals who were treated with the C5a receptor inhibitor avacopan as part of the phase 3 ADVOCATE trial, patients treated in the real-world setting had more severe renal disease ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...

Plans are underway for a phase 3 study with ABBV-3373. Investigators in a 2021 paper explored whether the C5a receptor inhibitor avacopan could effectively treat patients with antineutrophil ...

The company is prioritizing its INF904 program, which is an oral C5a receptor inhibitor, due to its market potential in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS).

This recommendation stems from promising topline results from the multiple ascending dose (MAD) part of a Phase 1 trial for InflaRx’s INF904, an innovative C5a receptor inhibitor. The medication ...

INF904 is an orally administered, small molecule inhibitor of the C5a receptor that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models. Further, in contrast to ...

INF904 is an orally administered, small molecule inhibitor of the C5a receptor that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models. Further, in contrast to the ...